Expression and Clinical Significance of Exosome Component 4 in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2023.06.013
- Author:
Jin-Quan HONG
1
;
Qing-Hua HUANG
2
;
Zhen-Yu HUANG
3
;
Li-Ping FAN
2
;
Qiu-Yan LIN
2
;
Hao-Bo HUANG
4
Author Information
1. Department of Anesthesia, The Second Affiliated Hospital, Fujian Medical University, Quanzhou 362000, Fujian Province, China.
2. Department of Blood Transfusion, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China.
3. School of Food and Bioengineering, Fujian Polytechnic Normal University, Fuqing 350300, Fujian Province, China.
4. Department of Blood Transfusion, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China,E-mail: huanghaobo1981@163.com.
- Publication Type:Journal Article
- Keywords:
clinical significance;
diffuse large B-cell lymphoma;
exosome component 4;
prognosis
- MeSH:
Humans;
Clinical Relevance;
Lymphoma, Large B-Cell, Diffuse/pathology*;
Prognosis;
Retrospective Studies;
Exosome Multienzyme Ribonuclease Complex/genetics*
- From:
Journal of Experimental Hematology
2023;31(6):1684-1689
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the expression of Exosome Component 4（EXOSC4） in the tissues of newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) and its clinical significance.
METHODS:The expression of EXOSC4 protein in the tissues of 181 newly diagnosed DLBCL patients was analyzed by immunohistochemical staining. Clinical data were collected. The correlation between EXOSC4 protein expression in the tissues of newly diagnosed DLBCL patients and clinical features were analyzed and its prognostic significance.
RESULTS:The positive rate of EXOSC4 protein expression was 68.51% in the tissues of 181 newly diagnosed DLBCL patients. These patients were divided into two groups, with 44 cases in high expression group and 137 cases in low expression group. There were no significant differences in age, gender, B symptoms, serum lactate dehydrogenase (LDH) level, Eastern Cooperative Oncology Group (ECOG) score, Ann Arbor stage, extranodal disease, International Prognostic Index (IPI) score, National Comprehensive Cancer Network IPI (NCCN-IPI) score, and cell origin between the two groups (P>0.05). Cox multivariate regression analysis showed that high EXOSC4 protein expression in tissues was an independent poor prognostic factor for OS and PFS in newly diagnosed DLBCL patients (all P<0.05). K-M survival analysis showed that newly diagnosed DLBCL patients with high EXOSC4 protein expression had significantly shorter overall survival (OS) and progression free survival (PFS) than those patients with low EXOSC4 protein expression (all P<0.05).
CONCLUSION:High EXOSC4 protein expression in tissues of newly diagnosed DLBCL patients is an independent poor prognostic factor for survival.
